focus -WSS

focus

author：fashion 2025-10-01 10:34:42 - browse：31896

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Hearing on Medicare drug price negotiation gets unusually heated

explore

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Experts study whether long Covid risk adds up with each reinfection

Radiation, mainstay of cancer treatment, begins a fade

Senate HELP committee spars over health care workforce policies

CDC's new outbreak response network to include Northeastern

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Supreme Court strikes down use of affirmative action

CDC advisory panel says seniors 'may' get RSV vaccine

Supreme Court strikes down use of affirmative action

How a symptom of dementia informs our understanding of creativity

United colonoscopy coverage change 'may cost lives,' doctors say

How Vertex's cystic fibrosis drug is changing patients' lives

George Santos makes 1st court appearance after pleading not guilty to 13 counts

NYU Langone launches private ChatGPT for its health care data

Jerome Adams on the need for new antivirals for Covid

Microbiome research is starting to find links to chronic diseases

leisure time

What AAP's gender

Drug for rare kidney disease narrowly misses mark in clinical trial

Microbiome research is starting to find links to chronic diseases

Complete sequence of Y chromosome published for first time

Complete sequence of Y chromosome published for first time

Senators: Long

explore

hotspot

leisure time

explore